现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2015年
9期
1253-1255
,共3页
膀胱癌%经尿道电切术%表柔比星%多柔比星脂质%膀胱灌注
膀胱癌%經尿道電切術%錶柔比星%多柔比星脂質%膀胱灌註
방광암%경뇨도전절술%표유비성%다유비성지질%방광관주
bladder cancer%transurethral resection of prostate%epirubicin%doxorubicin lipidosome%irrigation
目的：探讨经尿道电切术后膀胱灌注多柔比星脂质体治疗浅表性膀胱癌的临床疗效。方法：78例患者随机分为2组：表柔比星灌注组（EOX）和多柔比星脂质体组（DOL），随访比较2组患者术后复发情况和不良反应。结果：术后12个月和24个月，DOL 复发率分别为5.0%和10.0%，明显低于 EOX 复发率18.4%和26.3%（P <0.05）。DOL 组不良反应发生率低于 EOX 组（P <0.05）。结论：经尿道膀胱肿瘤电切术后膀胱灌注多柔比星脂质体疗效优于表柔比星而不良反应发生率低于表柔比星。
目的：探討經尿道電切術後膀胱灌註多柔比星脂質體治療淺錶性膀胱癌的臨床療效。方法：78例患者隨機分為2組：錶柔比星灌註組（EOX）和多柔比星脂質體組（DOL），隨訪比較2組患者術後複髮情況和不良反應。結果：術後12箇月和24箇月，DOL 複髮率分彆為5.0%和10.0%，明顯低于 EOX 複髮率18.4%和26.3%（P <0.05）。DOL 組不良反應髮生率低于 EOX 組（P <0.05）。結論：經尿道膀胱腫瘤電切術後膀胱灌註多柔比星脂質體療效優于錶柔比星而不良反應髮生率低于錶柔比星。
목적：탐토경뇨도전절술후방광관주다유비성지질체치료천표성방광암적림상료효。방법：78례환자수궤분위2조：표유비성관주조（EOX）화다유비성지질체조（DOL），수방비교2조환자술후복발정황화불량반응。결과：술후12개월화24개월，DOL 복발솔분별위5.0%화10.0%，명현저우 EOX 복발솔18.4%화26.3%（P <0.05）。DOL 조불량반응발생솔저우 EOX 조（P <0.05）。결론：경뇨도방광종류전절술후방광관주다유비성지질체료효우우표유비성이불량반응발생솔저우표유비성。
Objective:To study the curative effcet after Transurethral resection of prostate(TURP)irrigation of bladder doxorubicin lipidosome on superficial bladder cancer. Methods:All 78 patients were divided into two groups:Intravesical instillation of epirubicin group and doxorubicin lipidosome group. Results:12 months and 24 months after operation,the recurrence rate of doxorubicin lipidosome respectively were 5. 0% and 10. 0% ,significantly lower than that of epirubicin 18. 4% and 26. 3%(P < 0. 05). Incidence of adverse reaction in doxorubicin lipidosome was lower than epirubicin(P < 0. 05). Conclusion:The clinical curative effcet is better after TURP irrigation of bladder doxoru-bicin lipidosome than irrigation epirubicin hydrochloride,and with lower incidence of adverse reactions.
